Insmed Incorporated — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also reports unaudited fourth-quarter results; this is an annual report, not a standalone quarterly filing.
Business context
Insmed is a clinical-stage biopharmaceutical company focused on rare diseases. Its lead candidate, ARIKAYCE (liposomal amikacin for inhalation), was in a global Phase 3 study for refractory nontuberculous mycobacterial (NTM) lung disease caused by MAC, while its EU marketing application was under review. INS1009, an inhaled treprostinil prodrug, entered Phase 1 in late 2015. Insmed had no material commercial revenue.
Financial results and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $0 reported; French expanded-access revenue was immaterial and included in other income | $0 |
| Research and development expense | $74.3 million | $56.3 million |
| General and administrative expense | $43.2 million | $31.1 million |
| Operating loss | $117.5 million | $87.4 million |
| Net loss | $118.2 million; $2.02 per share | $79.2 million; $1.84 per share |
| Cash used in operating activities | $100.7 million | $64.4 million |
| Cash and cash equivalents at year-end | $282.9 million | $159.2 million |
| Working capital at year-end | $265.9 million | Not stated here |
| Total assets / shareholders’ equity | $356.6 million / $311.7 million | $230.9 million / $186.2 million |
| Debt | $25.0 million principal; 9.25% fixed rate | $25.0 million principal |
Margins are not meaningful given the absence of material revenue and ongoing operating losses. FY2015 financing cash flow was $227.8 million, chiefly reflecting $222.9 million net proceeds from an April public offering. Investing cash outflow was $3.5 million. No off-balance-sheet arrangements were reported other than operating leases.
Material changes versus prior period
- Net loss increased $39.0 million year over year as R&D rose $18.0 million and G&A rose $12.1 million; the income-tax benefit also fell by $8.4 million.
- R&D growth primarily reflected CONVERT Phase 3 clinical activity, INS1009 research, and higher manufacturing costs. G&A growth included European pre-commercial buildout and noncash stock compensation.
- Operating cash use increased $36.3 million. Cash rose by $123.7 million, principally because of the equity offering, despite operating cash burn.
- Outstanding shares increased from 49.8 million to 61.8 million, reflecting the 11.5 million-share offering and other share activity.
- In 2014 the company received a $10.4 million New Jersey NOL-sale tax benefit; the 2015 benefit was $2.0 million, and the company said it had reached the program’s lifetime cap.
Fourth-quarter 2015 revenue was $0, operating loss was $32.6 million, net loss was $31.2 million, and basic and diluted loss per share was $0.51. The comparable fourth-quarter 2014 net loss was $17.6 million, or $0.36 per share.
Outlook, commentary, risks and unusual items
- Management said available funds were sufficient for at least the next 12 months, while acknowledging that further capital may be needed. It expected no significant revenue for at least the next two years and anticipated continued losses.
- Management expected 2016 R&D expense to increase, mainly due to CONVERT, and G&A expense to increase, partly due to European pre-commercial spending. It expected to complete CONVERT enrollment in the second half of 2016 and anticipated a CHMP opinion on the ARIKAYCE application around mid-2016; these were forward-looking expectations, not results.
- The Phase 2 ARIKAYCE study did not meet its prespecified primary endpoint (p=0.072), although a key secondary culture-conversion endpoint favored ARIKAYCE (p=0.003). The ongoing Phase 3 study was intended to confirm efficacy. The filing also describes greater serious adverse events and discontinuations in the ARIKAYCE arm during the Phase 2 blinded period; two deaths were judged unrelated by the investigator.
- Key risks include clinical or regulatory failure or delay, uncertain approval and commercial uptake, reimbursement and pricing pressure, dependence on third-party manufacturers and a sole nebulizer supplier, and need for additional financing. The company also disclosed historical rat lung-carcinoma findings in a high-dose carcinogenicity study; FDA clinical holds related to the findings had been lifted in 2012, but the issue could still affect approval or labeling.
- The Hercules loan was extended to January 1, 2018; principal repayments were to begin in October 2016. The debt is secured by company assets other than intellectual property and includes restrictive covenants. Total disclosed contractual obligations were $39.0 million, excluding uncertain license milestones and royalties.
- Insmed withdrew the CF Pseudomonas indication from its EU application to focus resources on NTM. The 2015 statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting as of year-end.
Most important facts for investors to verify
- CONVERT enrollment, primary-endpoint results, safety findings, and whether the Phase 3 data support US and other regulatory submissions.
- EMA review milestones and outcome for the narrower MAC/NTM indication, including any requirement for additional studies or restrictions.
- Cash burn, 2016 spending and actual liquidity runway relative to management’s at-least-12-month assessment; also assess financing and dilution needs.
- Manufacturing scale-up and regulatory readiness at Therapure, and continuity of supply from Althea and sole device supplier PARI.
- Debt repayment schedule, covenant compliance, and the impact of financing and stock-based compensation on per-share ownership.